Their commitment to improving the quality of life for people with serious and rare conditions is evident in everything they do. Whether they are manufacturing and marketing effective products or researching and developing innovative biotherapies, they are first and foremost focused on fulfilling their customers’ needs.
CSL Behring is committed to improving the quality of life for patients with rare and serious diseases. The company develops, manufactures and markets a range of products including:
- Coagulation therapies – von Willebrand disease, haemophilia and congenital fibrinogen deficiency
- Immunology therapies – for hereditary angioedema, immune deficiency disorders, neurological disorders and haemolytic disease of the newborn
For more information about CSL Behring click here.